P2.04-92 Neoadjuvant Durvalumab With or Without Sub-Ablative Stereotactic Radiotherapy (SBRT) in Patients with Resectable NSCLC (NCT02904954)

Autor: Altorki, N., Borczuk, A., Saxena, A., Port, J., Stiles, B., Lee, B., Sanfilippo, N., Ko, E., Scheff, R., Pua, B., Gruden, J., Christos, P., Spinelli, C., Gakuria, J., Mittal, V., Mcgraw, T., Formenti, S.
Zdroj: In Journal of Thoracic Oncology October 2019 14(10) Supplement:S746-S746
Databáze: ScienceDirect